Clinical course of patients with relapsed multiple myeloma
Clinical course of patients with relapsed multiple myeloma
复制标题
DOI：
10.4065/79.7.867
复制
发表时间：
2004-07-01
影响因子：
8.9
通讯作者：
Greipp, PR
中科院分区：
文献类型：
--
作者：
Kumar, SK;Therneau, TM;Greipp, PR
目的：探讨多发性骨髓瘤（MM）患者经初始治疗后复发的临床过程。患者和方法：1985年1月1日至1998年12月31日期间在明尼苏达州罗切斯特市梅奥诊所就诊的MM患者，从前瞻性维护的数据库中确定。我们的研究人群包括578名新诊断的MM患者，他们在我们的机构进行了随访和整个临床过程的监测。结果：578例MM患者的中位年龄为65岁（范围26-92岁）；228例（39%）为女性。71例存活患者的中位随访时间为55个月（范围0-202个月）。578例患者在1年、2年和5年的总生存率（OS）分别为72%、55%和22%；初始治疗的中位OS为28.4个月。355例首次治疗后复发的患者的中位生存期为第二次治疗开始后17.1个月，84%在5年内死亡。反应持续时间随着每个连续的治疗方案而持续减少。血浆细胞标记指数高（大于等于1.0%）、血小板计数低(
OBJECTIVE: To study the clinical course of patients with multiple myeloma (MM) that relapses after initial therapy.PATIENTS AND METHODS: Patients with MM, seen at the Mayo Clinic in Rochester, Minn, between January 1, 1985, and December 31, 1998, were identified from a prospectively maintained database. Our study population consisted of 578 patients with newly diagnosed MM who were followed up and monitored throughout their clinical course at our institution.RESULTS: The median age of the 578 patients with MM was 65 years (range, 26-92 years); 228 patients (39%) were women. The median follow-up of 71 surviving patients was 55 months (range, 0-202 months). The overall survival (OS) for the 578 patients at 1, 2, and 5 years was 72%, 55%, and 22%, respectively; the median OS from initial therapy was 28.4 months. The median OS of 355 patients who experienced relapse after initial treatment was 17.1 months from initiation of the second therapy, and 84% died within 5 years. The duration of response decreased consistently with each successive regimen. Patients with a high plasma cell labeling index (greater than or equal to1.0%), low platelet count (